Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Phase II evaluation of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

Sordillo, Peter P., M.D.; Magill, Gordon B., M.D.; Gralla, Richard J., M.D.; Kelsen, David P., M.D.

American Journal of Clinical Oncology: June 1982 - Volume 5 - Issue 3 - p 273–276
Article: PDF Only
Buy

A PHASE II STUDY of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90–120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity. m-AMSA has little activity in patients with gastric adenocarcinoma.

From the Solid Tumor (PPS, GBM, DPK) and Developmental Chemotherapy (RJG) Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York.

© Lippincott-Raven Publishers.